Active	Status	Sponsor type	Region	Phase	Filter
3 Active 1 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Platten, Michael
AMPLIFY-NEOVAC, NCT03893903: AMPLIFYing NEOepitope-specific VACcine Responses in Progressive Diffuse Glioma	Active, not recruiting	1	60	Europe	IDH1R132H peptide vaccine, Avelumab	German Cancer Research Center	Malignant Glioma	09/24	12/24
INTERCEPT-H3, NCT04808245: A MultIceNTER Phase I Peptide VaCcine Trial for the Treatment of H3-Mutated Gliomas	Recruiting	1	15	Europe	Tecentriq 1200 MG in 20 ML Injection, Atezolizumab, H3K27M peptide vaccine, Imiquimod (5%), Aldara	German Cancer Research Center, Johannes Gutenberg University Mainz, Charite University, Berlin, Germany, Roche Pharma AG, German Cancer Aid	Newly Diagnosed H3-mutated Glioma	03/25	03/25
NCT05112549: Intrathecal Application of PD1 Antibody in Metastatic Solid Tumors With Leptomeningeal Disease (IT-PD1/ NOA 26)	Recruiting	1	46	Europe	Nivolumab [Opdivo]	University Hospital Tuebingen	Leptomeningeal Disease	09/25	09/26